L. Rydén

CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes

H. Rodbard, T. Battelino, P. Topsever, 2024, Cardiovascular diabetology.

Disparities in prevalence and treatment of diabetes, cardiovascular and chronic kidney diseases - Recommendations from the taskforce of the guideline workshop.

H. Rodbard, P. Topsever, Per Olav Vandvik, 2024, Diabetes research and clinical practice.

Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial

H. Gerstein, R. Coleman, L. M. Morrow, 2023, Journal of diabetes.

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

John E. Poremba, H. Randeva, P. Borne, 2024, The Lancet.

Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention).

H. Gerstein, Jacqueline Bosch, Cañada, 2008, American heart journal.